Maxim has started coverage of Autonomix (AMIX, Financial), giving it a Buy rating and setting a price target at $5. The company's platform technology is poised to revolutionize electrophysiology by detecting neural signals that indicate pain or disease and then neutralizing the responsible nerves. Initially concentrating on addressing pancreatic cancer pain, this innovative solution also holds promise for broader applications, including peripheral nervous system disorders, chronic pain management, hypertension, cardiovascular disease, and pain associated with other tumors.
The firm expresses confidence in Autonomix's financial health, noting that the company is well-funded to continue its operations through the third quarter of fiscal year 2026. This financial stability supports the company's ongoing technology development and potential market expansion.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Autonomix Medical Inc (AMIX, Financial) is $18.00 with a high estimate of $18.00 and a low estimate of $18.00. The average target implies an upside of 611.46% from the current price of $2.53. More detailed estimate data can be found on the Autonomix Medical Inc (AMIX) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Autonomix Medical Inc's (AMIX, Financial) average brokerage recommendation is currently 1.0, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
